In AML-11, AML-43, and AML-63, TP53-mutated AML was characterized by LOH, which was driven by the subfraction of leukemia initiating cells harboring both the mutation and del(17p) within a genetically heterogenous LSC pool. The gene discussed is TP53; the disease is leukemia.